EGFR and neoplasm: This nanoplatform incorporates the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib, Cu2+, and the photosensitizer ICG.[136] Osimertinib served as a chemotherapy agent, inhibiting EGFR‐mediated tumor proliferation, and delivered Cu2+ ions selectively targeted lipoylated proteins within the cellular tricarboxylic acid cycle, inducing protein aggregation and causing the loss of iron–sulfur (Fe–S) cluster proteins.